drugset

drugset / Trial / NCT01356940

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

NCT01356940 ↗

Phase 4 Completed 43 enrolled Brown, Theodore R., M.D., MPH Acorda Therapeutics · collab

RandomizedCrossoverTriple-blindTreatment

Summary

A randomized placebo controlled double-blind cross-over trial of Dalfampridine ER for effect on ambulatory activity in people with multiple sclerosis

Timeline

Start: 2010-11
Primary completion: 2013-04
Completion: 2013-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dalfampridine	Small molecule	10 mg	—

Indications